No Data
No Data
A-share changes | Q1 performance pre-increased, Colon Pharmaceuticals rose more than 5%, market capitalization nearly 50 billion yuan
Glonghui, April 11 | Colon Pharmaceutical (002422.SZ) rose more than 5%, and its stock price returned above 30 yuan, with a market value of nearly 50 billion yuan. According to the news, the company's net profit for the first quarter was 950 million yuan to 110 billion yuan, an increase of 16.64%-35.06% over the previous year. During the reporting period, the company increased market development and continued to optimize the product structure. Sales of infusion and non-infusion preparations increased, and profits increased year-on-year.
Express News | Colon Pharmaceuticals Performance Report: 2023 net profit increased 44.05% year-on-year
Colon Pharmaceuticals (002422.SZ): The core product, lucansastuzumab (sAC-TMT), published research results at the 2024 American Association for Cancer Research Annual Meeting
Colon Pharmaceuticals (002422.SZ) announced that its holding subsidiary, Sichuan Collenbotai Biomedical Co., Ltd. (“Colunbotai”), will announce its anti-TROP2 ADC lucansatuzumab (sAC-TMT) (formerly SKB264/) at the 2024 American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego, California, USA from April 5 to 10, 2024, at the poster presentation session from 1:30 p.m. to 5:00 p.m. local time on April 9, 2024 CT247 MK-2870) for both
Express News | Midday announcement: Ruihu Mold and Colon Pharmaceuticals suggest that convertible bonds will soon stop converting into shares
Parenteral Nutrition Market Global Analysis and Forecasts to 2030, Featuring Fresenius Kabi, Grifols, Pfizer, Otsuka Pharmaceutical, Baxter, Sichuan Kelun Pharmaceutical, Vifor Pharma and Aculife
Colon Pharmaceutical (002422.SZ): The subsidiary's core product SKB264 (MK-2870) was recognized as a breakthrough therapy by the State Drug Administration for first-line treatment of locally advanced, recurrent, or metastatic PD-L1 negative TNBC that cann
Gelonghui, March 13 | Colon Pharmaceutical (002422.SZ) announced that the company recently learned that the core product SKB264 (also known as MK-2870) of the company's holding subsidiary, Sichuan Colunbotai Biomedical Co., Ltd. (hereinafter referred to as “Columbite”), was recently recognized as a breakthrough therapy by the National Drug Administration (hereinafter referred to as “NMPA”) Drug Evaluation Center (TNBC) for first-line treatment of locally advanced, recurrent, or metastatic PD-L1 negative triple-negative breast cancer (TNBC). This is SKB264 follow-up treatment
No Data